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Recurrent respiratory papillomatosis (RRP) is a rare but potentially severe
disease caused by papillomavirus, most often types 6 and 11.  The disease,
which occurs in both juvenile and adult forms, is characterized by benign
epithelial tumors of the airway that most frequently affect the larynx but can
also spread along the entire aerodigestive tract.  Recurrent respiratory
papillomatosis is the most common benign neoplasm of the larynx in children
and the second most frequent cause of childhood hoarseness.  Standard
treatment, which is palliative only, consists of surgical excision of papillomata
to maintain airway patency and improve voice quality.  Recurrence despite
repeated surgical procedures is the rule.  To date, incorporation of adjuvant
treatments has not been reliably beneficial in altering the disease course.
Several case series have described promising results with cidofovir, a cytosine
nucleoside analog with antiviral activity.  To evaluate the data available on the
safety and efficacy of cidofovir for the treatment of RRP, we conducted a
MEDLINE search for all case reports or series from January 1966–August
2004 describing cidofovir therapy in either adults or children with RRP.  The
bibliographies of qualifying articles were also searched for relevant references.
In both adults and children with mild-to-severe RRP, intralesional
administration of cidofovir directly into the site of papillomata was associated
with partial-to-complete regression of papillomata, improvement in voice
quality and airway status, and decreased need for surgery.  Wide variation in
intralesional cidofovir dose (2–57 mg), frequency (every 2–8 wks), and
duration (4 mo–4 yrs) was found.  Successful outcomes have also been
reported with intravenous cidofovir, but data are limited to three case reports.
Rash, headache, and precordialgia were the only adverse effects reported with
intralesional cidofovir.  Nephrotoxicity and neutropenia secondary to either
intralesional or intravenous cidofovir were not observed.  Long-term risks
associated with intralesional administration remain to be seen.  Further
studies are necessary to determine the most appropriate dose, frequency, and
duration of therapy, and to fully characterize the safety profile of cidofovir
when given intralesionally.
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Recurrent respiratory papillomatosis (RRP) is a
rare disease caused by human papillomavirus
(HPV), most commonly types 6 and 11.1, 2
Papillomavirus is a small, nonenveloped virus
consisting of an icosahedral capsid enclosing a
double-stranded, circular DNA genome.  At least
70 HPV types have been identified, most of
which are associated with epithelial tumors of the
skin and mucous membranes, such as plantar
warts, condylomata acuminata (anogenital
warts), and epidermodysplasia verruciformis.3, 4
Recurrent respiratory papillomatosis is
manifested as exophytic lesions that most
frequently affect the larynx but can also spread
along the entire aerodigestive tract.  The presence
of these benign neoplasms can cause symptoms
ranging from dysphonia to life-threatening
respiratory distress, and can profoundly affect the
quality of life of patients with RRP.5, 6
Traditionally, RRP has been classified based on
patient age at diagnosis, such that two forms of
the disease have been described:  one with onset
in childhood, which is arbitrarily defined as
younger than 12 years (juvenile-onset RRP), the
other in adulthood (adult-onset RRP).  Juvenile-
onset RRP is observed more often and is typically
more aggressive than its adult counterpart.  Peak
age for the juvenile form is around 4 years,
compared with the third decade of life for the
adult form.7, 8 Among children, RRP is the most
common benign neoplasm of the larynx and the
second most frequent cause of hoarseness.9
Epidemiology
Accurate epidemiologic data for RRP are not
available.  The incidence of RRP among children
in the United States was estimated at 4.3/100,000
children, based on a survey questionnaire adminis-
tered in 1993 to board-certified U.S. otolaryn-
gologists.10 The incidence among patients aged
15 years or older was estimated at 1.8/100,000.
Each year, 1500–2500 new cases of juvenile-
onset RRP and 3600 new cases of adult-onset
RRP are diagnosed in the United States.  The
annual cost of managing juvenile-onset RRP is
$40–123 million.6 Males and females appear to
be nearly equally affected by juvenile-onset RRP
in contrast with adult-onset RRP, which
preferentially affects men.11
Transmission
The mode of HPV transmission resulting in
RRP is not well understood.  Studies have indi-
cated that similar HPV types are associated with
respiratory papillomatosis and condylomata
acuminata, and that at least 50% of mothers of
children with RRP have a history of genital tract
HPV disease.12–16 This led to the hypothesis that
juvenile-onset RRP is acquired through vertical
transmission.  In particular, it has been suggested
that birth to young primiparous mothers with
condylomata has been a risk factor for juvenile-
onset RRP.15, 16 However, in utero transmission of
the disease cannot be excluded and has been
suggested in reports of neonatal papillomatosis.17–19
Adult-onset RRP has been anecdotally associated
with a higher than expected number of lifetime
sexual partners and with oral-genital contact.20 It
is indeed evident that a clearer understanding of
the mode of RRP transmission is needed.
Clinical Features
The hallmark clinical manifestation of RRP
in children has been described as a triad of
relentlessly progressive hoarseness, stridor, and
respiratory distress.11 Chronic cough, recurrent
pneumonia, and failure to thrive may also occur.
Given these symptoms, a misdiagnosis of asthma
often leads to a delay in determining the true
airway pathology.  Progressive hoarseness is
almost universally the primary symptom in
adults.  Airway symptoms may occur in those
with advanced or aggressive disease but are much
less common than in pediatric patients.  Extra-
laryngeal spread of respiratory papillomata (most
frequently to the oral cavity, followed by the
trachea and bronchi) has been identified in
approximately 30% of children and 16% of adults
with RRP.  In the presence of aggressive disease,
spread of the papillomata into the tracheo-
bronchial tree and/or pulmonary parenchyma can
be fatal.10, 21, 22
Recurrent respiratory papillomatosis remains a
very frustrating disorder for patients and for
surgeons eager to perform a curative intervention.
Recurrence despite repeated surgery is the rule,
and to date, incorporation of adjuvant treatments
978
From the Departments of Pharmacy Services (Drs. Shehab
and Sweet) and Otolaryngology (Dr. Hogikyan), and the
Vocal Health Center (Dr. Hogikyan), University of Michigan
Health System, University Hospital, Ann Arbor, Michigan;
and the College of Pharmacy (Drs. Shehab and Sweet), the
Medical School (Dr. Hogikyan), and the School of Music
(Dr. Hogikyan), University of Michigan, Ann Arbor,
Michigan.
Address reprint requests to Nadine Shehab, Pharm.D.,
Department of Pharmacy Services, University of Michigan
Health System, University Hospital, 1500 East Medical
Center Drive, Room B2D301, Ann Arbor, MI  48109-0008;
e-mail:  nshehab@umich.edu.
CIDOFOVIR FOR RECURRENT RESPIRATORY PAPILLOMATOSIS  Shehab et al
has not been reliably beneficial in altering the
disease course.10 Recurrence has been attributed
to the persistence of latent virus in nondiseased
sites adjacent to areas that are clinically affected
by HPV.23, 24 Frequency of recurrence is highly
unpredictable, with extreme interpatient vari-
ability in the disease course.  Intrapatient vari-
ability also occurs, but is less striking than
interpatient variability.
Malignant conversion of previously benign
papillomatous lesions is rare, occurring in 3–5%
of patients with RRP.25 Malignant conversion is
most often associated with HPV types 16 and 18,
which have high malignant potential.  Exposure
to radiation and cytotoxic therapies (e.g.,
methotrexate) are risk factors for malignant
transformation.26–31 However, degeneration of
previously benign papillomata to squamous cell
carcinoma also can occur independent of any
such risk factors.32–34
Management
The current standard of care for RRP manage-
ment consists of surgical excision of respiratory
tract papillomata.  For patients with potential for
significant airway compromise, the primary goal
of treatment is improvement and maintenance of
an adequate airway.  For patients without airway
symptoms, the focus of treatment is improvement
of voice quality.  Given that cure is rare and
repeated procedures are expected, surgical
treatment decisions usually factor in the existing
pathology, potential for clinical decline, and
desire to extend the interval between operations,
if possible.
Papillomata typically are excised by direct
microlaryngoscopy and with the patient under
general anesthesia.  Specific excision techniques
vary and include traditional cold microlaryngeal
instruments, laser (most often carbon dioxide)
and, more recently, the microdebrider.35, 36 For
patients with severe symptomatic disease,
frequent surgical intervention (as often as every
2–4 wks) may be necessary.  Repeated surgery in
the same anatomic site increases the risk of
complications.  As many as 21–45% of patients
experience complications, such as mucosal
scarring, webbing, impaired vocal cord motion,
and subglottic or glottic stenosis.37–40 These
complications can affect voice quality and airway
patency.  In addition, surgical trauma may induce
new papilloma growth.41 Patients with aggressive
disease may require a tracheotomy to maintain an
airway; this, in turn, has been associated with
subsequent development of tracheal and stomal
papillomata.37, 42 If possible, tracheotomy should
be avoided in patients with RRP.
Surgery alone rarely cures RRP and is probably
best thought of as symptomatic treatment since it
does not address the underlying viral infection.
Approximately 10% of patients with more
aggressive disease require some form of adjuvant
therapy.11 Suggested criteria for starting adjuvant
therapy are the need for more than four surgical
procedures/year, distal multisite spread of the
disease, and rapid regrowth of papilloma disease
with airway compromise.11 Therapeutic modalities
used as adjunctive treatment for RRP are anti-
virals (cidofovir, acyclovir, ribavirin), bleomycin,
cimetidine, interferon a-2a and -2b, indole-3-
carbinol–diindolylmethane, methotrexate,
photodynamic therapy, and retinoids (cis-retinoic
acid, isotretinoin).43–67 However, none of these
approaches has been extensively studied, and no
single therapy or agent has consistently been
effective in eradicating RRP.  Interferon is one of
the more commonly studied adjuvant therapies,
but its use is limited by its unfavorable side effect
profile and high rate of disease resurgence on
discontinuation of treatment.51–57
Owing to the viral etiology of RRP, acyclovir, a
guanosine nucleoside analog, and cidofovir, a
cytosine nucleoside analog, have been studied as
adjuvant treatments for RRP.  One study described
the ideal antiviral drug for papillo-mavirus
infections as one that would eliminate existing
lesions, eradicate latent populations of viral
DNA, and allow for the development of natural
immunity to the virus.4 The rationale for the use
of acyclovir is less clear.  Unlike cidofovir, the
antiviral activity of acyclovir depends on the
presence of virus-specific thymidine kinase for
phosphorylation to its active metabolite.68 This
enzyme is not encoded by papillomavirus.4
Results of small studies examining the efficacy of
acyclovir for patients with RRP have been con-
flicting.43–45 Acyclovir may be effective for RRP
in the presence of coinfection with a virus capable
of activating acyclovir, such as herpes simplex
virus (HSV) or cytomegalovirus (CMV).43
Reports of intralesional cidofovir show more
promising results.  Cidofovir [(S)-1-3-hydroxy-2-
(phosphonylmethoxy)propyl]cytosine (HPMPC)]
is a prodrug that undergoes intracellular phos-
phorylation to its active metabolite, cidofovir
diphosphate (HPMPCpp), which then competi-
tively inhibits incorporation of deoxycytosine-5′-
triphosphate by viral DNA polymerase into the
viral DNA strand in a way that impedes viral
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DNA synthesis.68, 69 The precise mechanisms by
which cidofovir exerts its inhibitory effects on
HPV are not understood.  Cidofovir also
possesses activity against other viruses (e.g., HSV
and CMV).  However, unlike these, HPV relies on
the host cell DNA polymerase, and not a virally
encoded polymerase, for replication.4, 70
Induction of apoptosis and augmentation of host-
mediated immune responses have been proposed
as potential mechanisms of action of cidofovir in
RRP.70–72 Also, cidofovir may impede the carcino-
genesis of HPV-infected cells by downregulating
the expression of oncoproteins, leading to
restoration of tumor suppressor pathways.73, 74
Cidofovir demonstrates broad antiviral activity
against herpes viruses, such as thymidine-
kinase–producing and deficient HSV-1 and HSV-
2, varicella-zoster virus, CMV, Epstein-Barr virus,
human herpes viruses (types 6, 7, and 8), poly-
omavirus, papillomavirus, adenovirus, and pox-
viruses (e.g., variola virus, cowpox virus, monkey-
pox virus, camelpox virus, vaccinia virus, Orf
virus, and molluscum contagiosum).75 Cidofovir
is approved by the Food and Drug Administration
for treatment of CMV retinitis in patients with
acquired immunodeficiency syndrome.76
To evaluate the data available on the safety and
efficacy of cidofovir for the treatment of RRP, we
conducted a MEDLINE search for all case reports
or series from January 1966–August 2004
describing cidofovir therapy in either adults or
children with RRP.  The bibliographies of
qualifying articles were also searched for relevant
references.
Efficacy
The first reported use of intralesional cidofovir
injections to treat RRP was described in a 69-
year-old woman with squamous papilloma in the
hypopharynx and esophagus.72 Much of the data
since that report have been limited to case series
in which cidofovir was similarly administered as
an intralesional injection directly into the site of
each papilloma in adults and children with mild-
to-severe RRP (Table 1).77–87 In all these reports,
intralesional cidofovir injections were
administered to patients who received general
anesthesia.  In addition, one case series reported
office-based treatment with percutaneous
intralesional cidofovir injections.88 With the
exception of a few reports, cidofovir was used as
an adjuvant therapy to surgery or in combination
with other adjuvant agents.
Children
Investigators evaluated the efficacy of intra-
lesional cidofovir in five pediatric patients who
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Table 1.  Characteristics of Intralesional Cidofovir Treatment in Children and Adults with Recurrent Respiratory
Papillomatosis
Mean (range)
No. of Age Severity Total Dose No. of Duration of Frequency of
Patients (yrs)a Scorea, b (mg)c Injectionsd Therapy (mo) Injections
1077–79 4 (2–9) 18g NA (2.5–20.0) 8 (4–13)g 7.5 (3.8–13.5) Every 2–3 wks
179 9 20 NA (10.0–20.0) 28 51.0 NA
482 4 (3–7) NA 8.3 (2.0–15.0) 6 (6–7) 7.5 (7.0–8.0) Every 6–8 wks
683, h 7 (2–14) 12 (8–20) 5.6 (1.0–15.0) 4 4.0 Monthly
583, i 7 (4–10) 16 (8–25) 18.5 (10.0–30.0) 8 4.0 Monthly
1784 44 (11–77) NA 17.9 (2.5–42.5) 7 (2–15) 4.7 (1.0–13.0) Every 2 wks
1385 48 (18–85) 10 (2–29) 22.5 (2.5–37.5) 6 (1–19) 13.0 (7.3 days– Monthly
3.7 yrs)
10 JORRP86 13 (5–25) 10 NA 6 (2–20) 13.8 (NA) Monthly
16 AORRP86 37 (25–56) 5 4 (1–7) 9.9 (NA) Monthly
588 44 NA 47.0 (38.0–57.0) 7 (2–12) 12.0 (7.0–16.0) Every 2–4 wks
NA = not available; JORRP = juvenile-onset recurrent respiratory papillomatosis; AORRP = adult-onset recurrent respiratory papillomatosis.
aAt onset of cidofovir injections.
bReflects anatomic assessment of the papilloma stage as determined by the scoring system in reference.89
cTotal cidofovir dose/patient/session.
dRefers to total number of injections/patient over entire treatment period.
eComplete responders had no visible lesions, had a severity score of 0, or were disease free at end of cidofovir protocol or at follow-up.
fPartial responders had residual, relapsed, or recurrent disease at end of cidofovir protocol or at follow-up
gData were available for 9 of 10 patients.
hPatients received a single series of cidofovir 5-mg/ml injections.
iPatients with recurrent or recalcitrant RRP received an additional series of cidofovir 10-mg/ml injections.
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received cidofovir 2.5–5.0 mg/ml every 2–3
weeks for 4–13 months.77 Patients received 4–13
cidofovir injections every 2–3 weeks in
conjunction with surgical debulking and carbon
dioxide laser treatment.  Therapy was continued
until regression in papilloma growth was
observed.  In follow-up reports, the long-term
outcome for these initial five patients was
reported along with results for five new patients
who received four intralesional injections of
cidofovir 5 mg/ml every 2 weeks, and one
additional patient who received 28 injections
over a 51-month period.78, 79 All of these children
(aged 2–9 yrs) had aggressive RRP unresponsive
to adjuvant medical therapy and required
operative intervention every 2–6 weeks.  Severity
of their papillomatosis was graded using a
scoring system that entailed numeric grading (0
= absent, 1 = surface lesion, 2 = raised lesion, 3 =
bulky lesion).89 The extent of papilloma growth
was graded at 25 predefined aerodigestive
subsites such that 75 (i.e., a score of 3 at all 25
subsites) was the maximum allowable score.
During each session, the total dose of cidofovir
administered was 2.5–20 mg.
Complete remission, defined as the absence of
gross disease diagnosed by flexible endoscopy or
operative direct laryngoscopy, was observed in 5
of 11 patients who received a mean of 9.8 (range
4–13) injections over 5–9 months.  Of the
remaining children, five continued to have active
disease but no longer required cidofovir
injections to maintain patent airways.  These five
children received a mean of five (range 4–8)
injections.  Their mean RRP severity score
decreased from 17.8 (range 11–26) to 4.0 (range
2–6).  Of the entire cohort, one patient—who
was described as having recalcitrant disease and
an initial severity score of 20—showed a less
favorable response to cidofovir.  This was
demonstrated by the recurrence of papillomata
on discontinuation of intralesional injections.
After receiving 28 injections over a 51-month
period, the child’s severity score was 7.  The
authors of this case series reported the longest
mean follow-up time in the literature (37 mo
[range 7–66 mo]).79 Five patients in this case
series remained disease free for a mean of 51.6
months (range 39–66 mo).
The efficacy of cidofovir was also evaluated in
a small cohort of four pediatric patients (average
age 51 mo) with severe RRP requiring at least six
surgical excisions/year.82 Patients who had
received treatment with adjuvant chemotherapy
within the preceding 6 weeks were excluded
from the study.  At the time of endoscopic
debridement, cidofovir was administered at a
concentration of 5 mg/ml into sites in which all
visible papillomata were being excised.  A series
of six operations with cidofovir injections were
performed on each patient.  Each surgery was
performed 6–8 weeks apart over a period of 7
(three patients) or 8 (one patient) months.
Efficacy was evaluated throughout the treatment
period and was based on the change in severity
scores as defined by the grading system used.89
At 15-month follow-up, only one of the four
patients had complete resolution of disease,
described as the absence of papillomata and
clinical symptoms of RRP.82 Two patients
experienced an initial decrease in the severity
and/or extent of disease.  However, recurrence of
disease to pretreatment stages required further
frequent surgical intervention.  One patient with
diffuse disease affecting the trachea experienced
no resolution in growth of either the laryngeal or
the tracheal papillomata.  The author concluded
that although intralesional cidofovir was bene-
ficial in temporarily reducing the progression of
RRP, the benefit was no longer evident once
treatment was discontinued.
A prospective, nonrandomized case series
examined the effect of intralesional injections of
cidofovir, as an adjuvant to carbon dioxide laser
therapy, on the disease severity score of pediatric
patients with mild-to-severe RRP.83 Eleven
patients aged 2–14 years completed a series of
four monthly injections of cidofovir 5 mg/ml
(injection volume 0.2–3.0 ml).  Patients who had
recurrent or recalcitrant RRP 1 month after the
end of the initial series of injections were
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Table 1.  (continued)
No. (%) of Patients
Complete Partial
Responderse Respondersf Nonresponders
5 (50) 5 (50) 0
0 1 (100) 0
1 (25) 2 (50) 1 (25)
6 (100) 0 0
3 (60) 0 2 (40)
9 (53) 6 (35) 2 (12)
13 (100) — —
2 (20) 7 (70%) 1 (10%)
6 (37) 10 (63%) 0
0 5 (100%) 0
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subsequently treated with an additional series of
four monthly injections at an increased
concentration of 10 mg/ml (injection volume
1.0–3.0 ml).  Disease severity and extent of
subsite involvement were assessed using the
scoring system described above.
At the first follow-up period, 1 month after the
last injection, significant improvements in the
absolute and the percent change in severity and
subsite scores were observed across the 11
patients.  Seven (64%) had a complete (severity
score 0) or nearly complete (severity score 1)
response.  This response was maintained in six
(86%) of these seven patients at a mean ± SD
follow-up of 9.3 ± 7.2 months after the last
cidofovir injection.  Five patients required
treatment with the second series of four
injections.  Three of these five experienced
complete resolution of RRP; disease severity
scores remained unchanged in two patients with
moderate or advanced disease.  Mean time to
follow-up was 2 months (range 1–4 mo) after the
last cidofovir injection in the second series.
Although the results of this case series
suggested diminished treatment response in
patients with more severe disease, a positive
correlation between baseline disease severity
scores and treatment response was not evident by
statistical analysis (Spearman correlation
coefficient -0.62, 95% confidence interval -1.0 to
-0.03).  The authors concluded that intralesional
injections of cidofovir were effective at reducing
disease burden in children with RRP, but that
higher concentrations may be necessary for more
advanced disease, and patients with more severe
disease at baseline may be more resistant to
therapy.
Adults
In two case series describing intralesional
cidofovir in adults,84, 85 therapy was associated
with partial to complete remission of RRP in
most patients.  In the first report, 17 patients
aged 11–77 years (mean 44 yrs) received 2–15
(mean 7.2) intralesional injections of cidofovir
2.5 mg/ml (injection volume 1–12 ml).84 All
patients had biopsy-proven severe laryngeal RRP.
Initially, cidofovir was administered every other
week until a clinical response was noted, and at a
reduced frequency thereafter.  Two additional sets
of injections were administered at the previous
site of lesions when the last macroscopic lesion
had disappeared.  Follow-up consisted of indirect
laryngoscopy performed every 4 weeks on an
outpatient basis.
Intralesional cidofovir therapy was successful
in 14 patients.  Complete remission, with no
evidence of relapse, was observed in 9 of the 14
patients after a mean treatment duration of 3.3
months (range 1–8 mo).  Mean duration of
remission after the end of treatment in these nine
patients was 13.6 months (2–27 mo).  The
remaining five patients who responded success-
fully to therapy required additional injections for
relapsed lesions throughout their treatment
course.  Complete disease regression was observed
in two of these five, at 6 and 7 months, respectively,
after the last cidofovir injection.  Of the
remaining three, one progressed during cidofovir
therapy after an initial marked response, one had
partial remission and remained stable for more
than 1 year after the last injection, and one was
lost to follow-up after four injections.
The authors concluded that intralesional
cidofovir demonstrated a clear effect on the
progression of papillomatosis tumors, and that
their findings warrant further examination of the
effect of cidofovir on long-term outcomes in
patients with RRP.
In the second case series, the efficacy of
intralesional cidofovir in adults with RRP was
evaluated in an open-label, prospective study.85
Thirteen patients with biopsy-proven laryngeal
papillomatosis limited to the glottis, supraglottis,
or subglottis received monthly injections of
intralesional cidofovir until intraoperative
evaluation revealed no evidence of visible
papilloma.  Patients were then monitored for
recurrent disease with video laryngeal examination
every 3 months.  Excisional surgery was not
performed during cidofovir therapy.  Cidofovir
was administered at a concentration of 4.17–6.25
mg/ml (injection volume 0.6–6 ml, mean 3.8 ml).
At study completion, all patients had achieved
clinical remission, with no visible papilloma.
Patients were treated for a mean of 1.11 years
(range 7.3 days–3.7 yrs); lesion remission was
achieved after a mean of six injections (range
1–19).
Statistical analysis demonstrated a significant,
positive correlation between the number of
injections required until lesion remission was
achieved and both duration (p=0.005) and
severity of disease (p=0.05) before cidofovir
treatment was started.  The authors concluded
that intralesional injection of cidofovir is an
excellent treatment option, but noted that its
long-term efficacy in achieving remission
requires further study.
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Children and Adults
In the largest series of patients to undergo
adjuvant treatment with intralesional cidofovir,86
26 patients, both adults and children with mild-
to-severe biopsy-proven RRP, received at least
three monthly intralesional injections of cidofovir
5 mg/ml.  In addition, surgical debulking with
cold steel instruments or carbon dioxide laser
vaporization was performed in the setting of
airway obstruction or resistance to cidofovir
therapy.  Resistance was identified by persistence
of a lesion despite cidofovir treatment.  The
cidofovir protocol was started in patients with
adult-onset RRP (mean age 37 yrs), and in those
with juvenile-onset RRP (mean age 13 yrs).  The
volume injected during each procedure varied by
patient and was not reported.  Disease severity
was based on the same grading system as in the
previous case series discussed.  Patients with
juvenile-onset RRP had more severe and diffuse
disease than their adult counterparts.  This was
demonstrated by their mean severity scores at
baseline (juveniles 10.4, adults 5.1) and the
number of operations they had undergone before
cidofovir therapy.
At study completion, eight (31%) of the 26
patients were disease free, 17 (65%) showed
significant improvement, and 1 (4%) patient with
juvenile-onset RRP showed no improvement in
initial severity score despite six cidofovir
injections.  The reduction from baseline in mean
severity score was 75% (from 5.1 to 1.3) in the
16 patients with adult-onset RRP and 76% (from
10.4 to 2.5) in the 10 with juvenile-onset RRP.
However, the patients with juvenile-onset RRP
required a mean of six cidofovir injections (range
2–20) to achieve a similar extent of improvement
as those with adult-onset RRP, who received a
mean of four injections (1–7).
The authors discussed factors that may have
positively influenced the response to cidofovir in
their patient population:  older age at onset of
RRP (i.e., a diagnosis of adult-onset RRP),
papilloma growth at supraglottic subsites in
adults and glottic subsites in children, patient
adherence to the protocol, total number of
injections, and concomitant surgical excision.
Neither local nor systemic side effects secondary
to cidofovir therapy were noted throughout the
study or during the follow-up period, which was
a mean of 8 months (range 1–35 mo).
Percutaneous Intralesional Cidofovir Treatment
In the only case series to describe office-based
cidofovir treatment, five men with severe
laryngeal papillomatosis received percutaneous
intralesional cidofovir injections.88 The
treatment goal was to minimize the need for laser
surgery under general anesthesia.  Before the start
of cidofovir treatment, patients had required
operative intervention every 2.8 months on
average.  Cidofovir injections were initially
administered every 2–4 weeks, then at longer
intervals depending on therapeutic response.  All
five patients underwent laser ablation of papillo-
mata at the beginning of percutaneous treatments.
Although papilloma volume was reduced in all
patients, none experienced complete remission,
and two of the five subsequently required
operative intervention.  Residual papillomatous
lesions were present in the anterior commissure
in one of these two patients and in the left
aryepiglottic fold of the other; both required
further surgical treatment.  The authors sug-
gested that percutaneous intralesional cidofovir
injections may be useful as adjunct therapy, but
not as a replacement for laser ablation in adult
patients with papillomata involving the vocal
cords and anterior commissure.
Intravenous Cidofovir Treatment
Three case reports described systemic rather
than intralesional administration of cidofovir for
treatment of RRP.90–92 In the first report, a 35-
year-old woman with a history of laryngeal
papillomatosis diagnosed at infancy was having
daily episodes of hemoptysis and progressive
dyspnea on exertion.90 She had already undergone
treatment with a total of 96 resections and laser
ablations.  Computed tomography of the thorax
revealed several bilateral pulmonary nodules and
cysts.  A presumptive diagnosis of HPV-related
multicystic lung disease was made, and treatment
with intravenous cidofovir 5 mg/kg was begun.
Cidofovir was administered biweekly in con-
junction with probenecid for 2 months, followed
by aggressive hydration to minimize the risk of
cidofovir-associated nephrotoxicity.  In anticipation
of cessation of cidofovir therapy, interferon a-2a
was started.
After 9 months of concomitant cidofovir and
interferon therapy, the patient developed alopecia
and leukopenia necessitating discontinuation of
interferon and a dose reduction in cidofovir.
Cidofovir 4 mg/kg was continued every 2 weeks
for an additional 12 weeks and was stopped after
the patient had received a total of 51 doses over
24 months.  Eighteen months after cessation of
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all therapy, the patient was doing well, as
evidenced by normal pulmonary function test
results, stabilization of parenchymal disease, and
the need for only one laser surgical treatment.
The second report described the administration
of intravenous cidofovir in a 34-year-old woman
with diffuse RRP extending from the larynx to
the trachea.91 Her disease was refractory to
repeated excisional surgery and a 4-year course
of interferon a-2b therapy.  The patient had
undergone more than 200 microlaryngoscopies
since the age of 7 years and suffered from voice
problems and recurrent pneumonia due to
bronchial obstruction.  Interferon a-2b therapy
was discontinued, and therapy was started with
intravenous cidofovir 5 mg/kg once/week for 2
weeks, followed by 5 mg/kg every 2 weeks.
Treatment with cidofovir was continued for 2
months before interferon a-2b was reinstituted
due to recurrence of papillomatosis in the larynx.
One year after combination therapy, examination
indicated complete macroscopic disappearance of
the patient’s laryngeal lesions, marked response
of the papillomata in the trachea, and regression
of the endobronchial lesions and intrapulmonary
consolidations.
The third case report described an 8.5-year-old
girl with RRP of the pharynx, larynx, trachea,
and lungs.92 Intravenous cidofovir 5 mg/kg was
administered over 1 hour with the following
schedule:  once/week for 4 weeks, every other
week for 8 weeks, every third week for 9 weeks,
every 4–6 weeks for 21 weeks and, in the last
month, once/week for 4 weeks.  In addition, oral
probenecid 25 mg/kg and intravenous hydration
were administered before and after each cidofovir
dose.  Cidofovir was given as a single therapy for
4 months before surgical treatment with carbon
dioxide laser became necessary to preserve
airway patency. Also, adjuvant therapy with
indole-3-carbinol was begun after 14 doses of
cidofovir.
Disappearance of the pharyngeal papillomata
was noted at 6 months, bronchial papillomata at
8 months, and laryngeal papillomata at 9 months
after the start of cidofovir therapy.  Progression of
tracheal lesions was reduced after 10 months of
therapy. No local or systemic adverse effects
secondary to cidofovir were observed throughout
the 12-month treatment period.
Safety
The most common and severe adverse effects
of systemically administered cidofovir are
nephrotoxicity and neutropenia.76 With the
exception of one patient who developed
leukopenia while receiving interferon and
intravenous cidofovir concomitantly, these
adverse effects have not been reported in the
literature describing the use of cidofovir for
RRP.90 Given the low doses administered in the
treatment of RRP and the local nature of
administration, the likelihood of these systemic
toxicities resulting from intralesional cidofovir
therapy is minimal.
To assess the extent of systemic absorption of
intralesional cidofovir, a group of investigators
measured serum cidofovir concentrations in
three patients receiving intralesional injections of
cidofovir every other week.84 A total of five
series of cidofovir serum concentrations were
obtained at various times, and up to 48 hours
after the end of the cidofovir injection.  Serum
cidofovir was detectable in two of the three
patients 5–15 minutes after the intralesional
injection; the highest and lowest concentrations
were 0.6 and 0.36 µg/ml, respectively.  These
concentrations are considerably lower than those
achieved with systemic administration of
cidofovir. Pharmacokinetic studies have reported
peak serum cidofovir concentrations of 7 and 24
µg/ml after 1-hour cidofovir infusions of 3 and
10 mg/kg, respectively.93
The safety of intralesional cidofovir injections
has also been evaluated in animals.94 Canine
subepithelial vocal folds were injected biweekly
for 6 months with cidofovir 2.5–37.5 mg
(injection volume 0.5 ml).  At the end of the 6-
month injection period, dose-dependent
histopathologic changes noted were endomysial
edema with muscle fiber separation, atrophy, and
scarring of vocal folds.  Onset of atrophy and
scarring was observed after 3, 7, and 11
injections in the vocal folds with cidofovir 3.5,
20, and 10 mg, respectively.
Six months after the end of the last injection,
resolution of histologic abnormalities was
complete in the vocal folds of animals given low-
dose cidofovir 2.5 mg, nearly complete in those
given intermediate-dose cidofovir 5 or 10 mg,
and not apparent in those given high-dose
cidofovir 20 or 37.5 mg.  Complete blood counts
and renal parameters were unchanged through-
out the injection period.  The investigators
concluded that intralaryngeal cidofovir in
animals leads to dose-dependent scarification of
the vocal folds that appears to be irreversible at
higher doses of cidofovir and that lower
concentrations of this drug should be reserved
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for intralesional administration.
Long-term risks associated with intralesional
cidofovir administration in patients with RRP
have not been well studied.  Overall, few adverse
events have been recorded in the published
reports.  In a case series discussed earlier,84 two
adult patients developed a cutaneous rash after a
single intralesional cidofovir injection.  However,
whether this effect was a direct result of cidofovir
administration is unclear, since the rash did not
recur in either patient during subsequent cidofovir
treatment.  In the same series, another adult
experienced headaches after each intralesional
cidofovir injection that responded to symptomatic
treatment.  One patient complained of precor-
dialgia after receiving three cidofovir injections.
Intralesional injections in this case series were
not associated with any local adverse reactions,
such as inflammation, scarring, or fibrosis.
In contrast, another group of authors
frequently noted a local inflammatory response at
the injection site 7–14 days after each
intralesional cidofovir injection.85 However, the
authors stated that this response was not
associated with any new areas of scarring, web
formation, or impaired vibration of the vocal fold
mucosa.  In the case series describing treatment
with percutaneous intralesional cidofovir
injections,88 the only complaint patients reported
was mild stinging during administration of the
drug.  An effect of cidofovir on complete blood
cell counts and blood chemistry profiles was not
observed with intralesional administration.79, 82, 84,
86, 88 Airway compromise during cidofovir
injections was not reported in any of the case
series.
Of theoretic concern is the possibility that
intralesional cidofovir may lead to malignant
transformation at the injection site.  Although no
data suggest that intravenous cidofovir is
carcinogenic, subcutaneous cidofovir injections
in rats were associated with development of
adenocarcinoma.77, 95 This effect was not
observed in primates, however.95 Neoplastic
changes have not been reported in any of the case
series in which cidofovir was administered
intralesionally or intravenously to children or
adults with RRP.  One case series described two
patients with a diagnosis of verrucous carcinoma,
but the authors ultimately felt that this disease
was present before cidofovir treatment.84
The question of whether cidofovir leads to
development of laryngeal carcinoma is confounded
by previous observations that HPV itself may
predispose patients to development of squamous
cell carcinoma in both laryngotracheal and
bronchoalveolar areas.  Long-term follow-up of
patients receiving intralesional cidofovir is
necessary to fully understand the potential
carcinogenicity of cidofovir therapy.
Dosage and Duration of Therapy
The optimal dose, frequency, and duration of
intralesional cidofovir therapy for patients with
RRP have yet to be determined.  Whether a direct
relationship exists between dose or duration of
therapy and positive clinical outcomes is not
clear.  For treatment of CMV retinitis, cidofovir is
administered as a 5-mg/kg infusion once/week
for 2 weeks, followed by the same dose once
every other week.76 Intralesional cidofovir was
administered well below this dose to patients
with RRP. Administration of higher doses may
have contributed to improved patient outcomes
in two case series.84, 85 However, inclusion of
adult patients in both series also may have
positively influenced clinical outcomes, since the
disease course is less aggressive in adults than in
children.
Another study also administered higher doses
of cidofovir 38–57 mg in the adult cohort.88
However, in contrast to the two case series,84, 85
none of the study patients achieved complete
remission with percutaneous cidofovir treatment.
Based on findings from their stepped-dose
cidofovir protocol, the authors of one case series
concluded that some patients may benefit from
an increased dose if they do not respond to a
series of cidofovir 5-mg injections.84 This gives
clinicians a strategy for evolving the use of this
promising treatment when initial results in a
particular patient are suboptimal.
However, long-term risks associated with
intralesional administration of high cidofovir
doses have not been adequately studied.
Administration of high cidofovir doses led to
scarification of the vocal cords in a canine
model94 but has not been described in humans.
Physicians and patients must balance consider-
ation of disease severity with a degree of uncertain
risk when considering escalated treatment
regimens.
The frequency of injections reported in the
literature also varies, with most treatments
administered from every 2 weeks to once/month.
For the most part, timing of cidofovir injections
correlated with timing of excisional surgery.  In
one study, the rationale for biweekly cidofovir
injections was based on the intracellular half-life
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of cidofovir’s active metabolite, cidofovir
diphosphate.79 The intracellular half-life of
cidofovir diphosphate has ranged from 17–24
hours.  Other studies have suggested that
formation of another cidofovir metabolite,
HPMPCp-choline adduct, with a reported
intracellular half-life of 48 hours, produces a
reservoir of drug from which the active
metabolite is slowly released.69, 96, 97
In vitro, cidofovir demonstrated antiviral
efficacy against HSV-1 even after discontinuation
of drug treatment.96 The investigators attributed
the persistence in cidofovir’s antiviral efficacy to
slow clearance of its metabolites from the cell.
The long intracellular half-life of cidofovir allows
for weekly administration during induction and
every-other-week administration during
maintenance therapy for CMV retinitis.  One of
the series described previously used a cidofovir
injection frequency of every 6–8 weeks,82
compared with biweekly or monthly regimens
reported by other authors.  This may have
contributed to the finding that only one of four
patients in the series demonstrated a complete
response as a result of cidofovir treatment, and it
would suggest that a shorter interval between
injections may be warranted.
Given the significant variability in the
presentation and progression of RRP, it is unlikely
a single interval between cidofovir treatments
that is appropriate for all patients can be defined.
Most of these injection series were performed in
the operating room, using direct laryngoscopy
and general anesthesia.  Therefore, practical,
medical, and financial factors, aside from drug-
related factors, will ultimately be determinants of
the most appropriate dosage regimen and
treatment approach for each patient.
Duration of therapy has also varied greatly
among case series.  Several patients experienced
marked improvement in their severity scores and
airway status.  However, after discontinuation of
cidofovir injections, they experienced recurrence
of papillomata requiring medical intervention.  In
one report, only one of five patients treated with
only four cidofovir injections experienced
complete remission.79 Similarly, five (46%) of the
11 patients in another study required additional
treatment after the initial series of four
injections.83 These patients had mild or
moderate-to-advanced disease at baseline.
Basing duration and frequency of cidofovir
therapy to the life cycle of HPV has also been
suggested, so that treatment is administered
when the virus is in its active phase, and
cidofovir can interfere with viral DNA
synthesis.83 However, a test that can be used in
clinical practice to determine when HPV is in its
active phase does not appear to be available at
this time.
Limitations of the Literature
Most case series have reported positive
outcomes with administration of intralesional
cidofovir, and enthusiasm for its use in patients
with RRP seems justifiably high.  However,
several questions remain as to what role cidofovir
should play as an adjuvant therapy.  Results of
the case series are limited by small study
populations as well as a lack of control groups
and a blinded study design.  In many of the case
series and case reports, patients underwent
surgical debulking or received other adjuvant
therapies in addition to intralesional or intra-
venous cidofovir, thereby hindering the ability to
attribute any positive outcomes solely to
cidofovir. It remains to be seen whether the
positive results in the case reports that described
concomitant administration of cidofovir and
interferon reflect a synergistic effect on the
inhibition of HPV proliferation, as has been
demonstrated in vitro.90, 91, 98
Furthermore, it is well established that the
disease course and severity of RRP are characterized
by significant interpatient and intrapatient
variability.  Although some patients may experience
spontaneous remission, others may experience
aggressive regrowth of papillomata despite
repeated surgical and pharmacologic interventions.
The unpredictable nature of RRP makes it
difficult to evaluate the efficacy of cidofovir for
treatment of the disease in a controlled setting.
Also unclear from the literature is whether
cidofovir would preferentially show increased
efficacy against certain HPV types, since HPV
typing was not performed for all study patients.
Some data suggest that infection with HPV-11 is
associated with more aggressive disease than
infection with HPV-6.  However, viral subtypes
generally have not shown substantial differences
in response to different adjuvant therapies.82, 99
The literature is not clear as to whether the
efficacy of intralesional cidofovir varies depending
on the site of the papillomatous lesions and the
ability to achieve therapeutic drug concentrations
in HPV-infected cells.  Successful outcomes with
intralesional and intravenous cidofovir therapy
have been reported in patients with localized and
diffuse disease extending from laryngeal to
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tracheobronchial regions.  One group of authors
suggested that an inverse correlation might exist
between the efficacy of cidofovir and baseline
disease severity.83 However, the statistical
analysis performed with their small study
population demonstrated that disease severity
was not predictive of a poor response to cidofovir.
Conclusion
Recurrent respiratory papillomatosis is a rare,
potentially fatal disease characterized by
numerous recurrences and refractoriness to
surgical and various adjuvant treatments.
Cidofovir, an antiviral agent with activity against
HPV, the causative agent of RRP, has shown
promising results for adjuvant treatment of RRP
in both adults and children.  In patients with
mild-to-severe disease, cidofovir administered
either intralesionally or intravenously has
resulted in partial to complete regression of
papillomata, improvement in voice quality, and
decreased need for surgery.  Further studies are
necessary to determine the most appropriate
dose, frequency, and duration of therapy, and to
more fully characterize the safety profile of
cidofovir administered as an intralesional
injection.
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